What is HC Wainwright’s Forecast for InflaRx Q3 Earnings?

InflaRx N.V. (NASDAQ:IFRX) – Equities research analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for InflaRx in a research note issued on Thursday, March 19th. HC Wainwright analyst M. Keller expects that the company will earn ($0.15) per share for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for InflaRx’s Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.51) EPS and FY2028 earnings at ($0.52) EPS.

Several other research firms also recently weighed in on IFRX. Leerink Partners reiterated a “market perform” rating and issued a $2.00 target price (down from $5.00) on shares of InflaRx in a research note on Wednesday, December 3rd. Raymond James Financial reaffirmed an “outperform” rating on shares of InflaRx in a report on Wednesday, December 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research note on Monday, December 29th. Finally, Guggenheim lowered their target price on shares of InflaRx from $22.00 to $14.00 and set a “buy” rating on the stock in a report on Friday. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.17.

InflaRx Stock Up 3.3%

NASDAQ IFRX opened at $0.94 on Monday. The company has a market cap of $63.69 million, a PE ratio of -1.24 and a beta of 1.48. InflaRx has a 52 week low of $0.71 and a 52 week high of $1.94. The firm’s 50-day simple moving average is $0.93 and its two-hundred day simple moving average is $1.14.

InflaRx (NASDAQ:IFRX) last released its earnings results on Thursday, March 19th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.17). The firm had revenue of ($0.04) million during the quarter, compared to analysts’ expectations of $0.03 million.

Institutional Trading of InflaRx

Several institutional investors and hedge funds have recently bought and sold shares of the company. Cubist Systematic Strategies LLC boosted its holdings in InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares during the period. HRT Financial LP bought a new position in shares of InflaRx in the fourth quarter worth $47,000. Concurrent Investment Advisors LLC raised its position in shares of InflaRx by 56.9% in the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after buying an additional 19,200 shares in the last quarter. Insigneo Advisory Services LLC purchased a new stake in shares of InflaRx in the fourth quarter worth $61,000. Finally, Quadrature Capital Ltd bought a new stake in InflaRx during the fourth quarter valued at $104,000. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about InflaRx

Here are the key news stories impacting InflaRx this week:

• Positive Sentiment: Company highlights promising Phase 2a izicopan data, progress toward Phase 2b readiness in hidradenitis suppurativa (HS), plans for PK bridging in China, active collaborator discussions, and a spring Capital Markets Day to outline the development path—these clinical and strategic updates are the main near‑term catalysts. InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
• Positive Sentiment: Guggenheim maintained a Buy rating while lowering its price target from $22 to $14 — the cut reduces upside vs prior expectations but the firm still signals conviction in the story, which can support the stock. Guggenheim price target note (Benzinga)
• Positive Sentiment: HC Wainwright continues to carry a Buy rating with a $6 target and published near‑term EPS estimates (Q1 2026: -$0.14; Q2 2026: -$0.13), providing analyst support and a clear set of expectations for upcoming quarters. HC Wainwright estimates (MarketBeat)
• Neutral Sentiment: InflaRx reported Q4 EPS of ($0.17), which met consensus, reducing near‑term headline risk from the print itself. Press Release
• Neutral Sentiment: Market coverage and public filings (Business Insider / GlobeNewswire) provide a fuller corporate update on milestones and timelines; these items clarify strategy but do not immediately alter cash or clinical risk. InflaRx full‑year results (Business Insider)
• Negative Sentiment: Revenue remains negligible and the company reported revenue below estimates; InflaRx is still loss‑making with consensus full‑year EPS around -$1.04, underlining ongoing financing and execution risk. Zacks: Q4 loss, revenue miss
• Negative Sentiment: Cash, cash equivalents and marketable securities totaled €46.2M at 12/31/25, which the company says funds operations to mid‑2027 — this finite runway implies potential dilution or financing needs if clinical programs extend or expand. InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.